Needham & Company LLC Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price increased by Needham & Company LLC from $205.00 to $210.00 in a research report released on Wednesday,Benzinga reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

JAZZ has been the subject of a number of other reports. Royal Bank of Canada restated an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Piper Sandler restated an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $182.47.

Jazz Pharmaceuticals Trading Up 3.2 %

Shares of NASDAQ JAZZ opened at $144.17 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market capitalization of $8.72 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $148.06. The business has a fifty day moving average price of $125.42 and a 200 day moving average price of $118.44.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 5,053 shares of company stock valued at $617,442. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors have recently bought and sold shares of JAZZ. Fuller & Thaler Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after purchasing an additional 507,234 shares during the period. Darwin Global Management Ltd. purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $59,668,000. Dimensional Fund Advisors LP lifted its position in shares of Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after acquiring an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp lifted its position in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after acquiring an additional 296,800 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.